Drug intelligence / Profile preview

EDI-M405

Development stage: Preclinical
Lead developer: Empire Discovery Institute
Modality: Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

EDI-M405 is a preclinical-stage vaccine candidate developed by the Empire Discovery Institute (EDI). It is designed to induce an immune response against antigens from *Moraxella catarrhalis*, a common respiratory pathogen. The primary indications for EDI-M405 are the prevention and treatment of exacerbations in Chronic Obstructive Pulmonary Disease (COPD) and the prevention of Otitis Media (middle ear infections) in children. *M. catarrhalis* is a significant contributor to the inflammatory burden in these conditions, and a successful vaccine could reduce antibiotic usage and disease morbidity.

Beyond the preview

Go deeper on EDI-M405.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on EDI-M405.

Explore the full profile